Summary
Professor Ray is currently Professor of Public Heath in the Department of Public Health and Primary Care at Imperial College London , Honorary Consultant Cardiologist at the Imperial College NHS Trust and Director of ICTU-Global which is an academic ARO.
He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, my MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge.
His research involves lipids, diabetes and population health serving as global lead for trials and registries. Since 2018 Professor Ray has been recognised by Clarivate Analytics as among the top 0.1% of authors in global medicine. In 2023 he was inducted as a Fellow of the Academy of Medical Sciences, which is UK’s highest honour for clinician scientists.
His research interests have focused on the prevention of cardiovascular disease with a special interest in lipids and diabetes. He has investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. These have influenced AHA/ACC and ESC guidelines. His work on statins and diabetes risk led to a global label change for statins by the FDA and EMEA. He continue to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis and coronary events. He has received research grants including from the British Heart Foundation, the Wellcome Trust, Pfizer, Amgen, Sanofi, MSD, and the European Atherosclerosis Society (EAS). Currently he leads the EAS Familial Hypercholesterolaemia (FH) Studies collaboration which is the first global registry for FH and now includes approximately sixty countries, and is in the Senior PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London.
Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap, Chair for Global Council for Heart Health, National Lead for CVD NIHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now. He is a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians. He has been the national lead investigator and have served on the steering and executive committees for several major medical trials. He is currently involved in eight trials including PI of ORION 1 and BETONMACE.
He has published over 200 research articles in numerous journals including the NEJM, Lancet, JAMA, Archives of Internal Medicine, Circulation, the Journal of the American College of Cardiology, and the European Heart Journal, which have been cited over 150,000 times.
Publications
Journals
Watts GF, Gidding SS, Hegele RA, et al., 2023, International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia, Nature Reviews Cardiology, Vol:20, ISSN:1759-5010, Pages:845-869
Makris A, Barkas F, Sfikakis PP, et al., 2023, Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?, Atherosclerosis Plus, Vol:54, ISSN:2667-0895, Pages:1-6
Lyons ARM, Stevens CAT, Dharmayat KI, et al., 2023, Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia., Indian Heart J
Mohamed AA, Ray KK, 2023, Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives., Curr Opin Cardiol, Vol:38, Pages:527-532
Sabouret P, Ecarnot F, De Rosa S, et al., 2023, What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives, European Heart Journal, ISSN:0195-668X